---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-26-000022"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:41:48.819413+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M

## Summary
- Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
- Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).
- Raised FY2026 revenue guidance to $797-803M (prior range not specified).
- Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.
- Cash and marketable securities $146M at quarter end.

## SEC filing metadata
- accession: 0001077183-26-000022
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/neo-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-26-000022
- JSON: https://secwatch.observer/filing/0001077183-26-000022.json
- Plain text: https://secwatch.observer/filing/0001077183-26-000022.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported first quarter of 2026 results: revenue $187 million, net income $17 million. Guidance raised.
  - Period: first quarter of 2026
  - Revenue: $187 million
  - Net income: $17 million
  - Guidance: raised
  - Result: reported results
  source text: Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm
- Earnings Releases
  NEOGENOMICS INC reported full-year 2026 results: revenue $797-$803 million. Guidance raised.
  - Period: full-year 2026
  - Revenue: $797-$803 million
  - Guidance: raised
  - Result: guidance update
  source text: Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.